Opioid-based analgesics are widely used for treating chronic pain, but opioids are highly addictive when repeatedly used because of their strong rewarding effects. In recent years, abuse of prescription opioids has dramatically increased, including incidences of misuse of opioid drugs prescribed for pain control. Despite this issue in current clinical pain management, it remains unknown how pain influences the abuse liability of prescription opioids. Pain as aversive experience may affect opioid reward of positive emotion through common brain sites involved in emotion processing. In this study, on a rat model of chronic pain, we determined how persistent pain altered behavioral responses to morphine reward measured by the paradigm of unbiased conditioned place preference (CPP), focusing on GABAergic synaptic activity in neurons of the central nucleus of the amygdala (CeA), an important brain region for emotional processing of both pain and reward. We found that pain reduced the minimum number of morphine-conditioning sessions required for inducing CPP behavior. Both pain and morphine conditioning that elicited CPP inhibited GABA synaptic transmission in CeA neurons. Pharmacological activation of CeA GABA A receptors reduced the pain and inhibited CPP induced both by an effective dose of morphine and by a sub-threshold dose of morphine under pain condition. Furthermore, inhibition of CeA GABA A receptors mimicked the pain effect, rendering the subthreshold dose of morphine effective in CPP induction. These findings suggest that pain facilitates behavioral responses to morphine reward by predisposing the inhibitory GABA function in the CeA circuitry involved in the behavior of opioid reward.
INTRODUCTION
Opioids such as morphine and its derivatives have been the mainstay of therapies for clinical pain control over the past decades. Although opioids are highly effective for pain inhibition, they are known to induce severely aversive side effects, including analgesic tolerance, physical dependence, and opioid addiction (Ballantyne and LaForge, 2007; Bhargava, 1994; Woolf and Hashmi, 2004) . Opioid addiction is a chronic psychiatric disease and is pharmacologically driven partly by the strong rewarding effects of opioids. Concerns about the risk of opioid abuse significantly hamper their optimal use in treatment of chronic pain conditions. In fact, incidences of prescription opioid abuse have been considerably increased in recent years and the risk of developing prescription opioid abuse may be underestimated (Boscarino et al, 2010; Edlund et al, 2010; McCabe et al, 2008) . Opioid analgesics are among the most frequently abused drugs (Johnston et al, 2004) and epidemiological surveys have shown increased risk of abuse of opioid analgesics in patients with chronic pain (Compton and Volkow, 2006; Sullivan and Ferrell, 2005) . Although clinical studies have implicated that the reinforcing effect of opioids differs in different chronic pain states (Banta-Green et al, 2010; Kahan et al, 2006; Pohl and Smith, 2012) , it is still unknown how pain may alter the rewarding properties of opioids and consequently the risk of opioid abuse in treatment of chronic pain with opioids.
The amygdala is a key brain structure that regulates emotional responses to negative and positive stimuli. The central nucleus of the amygdala (CeA), as the major output of amygdalar nuclei, is important in regulation of the emotional aspects of chronic pain (Fields, 2000; Neugebauer et al, 2004) . It also has a critical role in the learning process of stimulus-reward association (Baxter and Murray, 2002; Bie et al, 2012; Gottfried et al, 2003; Le Merrer et al, 2009 ). Thus, CeA converges emotional stimuli associated with chronic pain and addictive opioids, providing an appropriate neural system to investigate interactions between pain and opioid reward. Central synaptic transmission is a main target of abused drugs and drug-induced synaptic plasticity, which outlasts the presence of drugs in the brain, has been critically implicated in the mechanisms for drug reward and addiction (Koob and Volkow, 2010; Luscher and Malenka, 2011; Russo et al, 2010) .
In the present study on a rat model of chronic pain, we examined the effect of pain on behavioral responses to morphine reward, focusing on GABA synaptic function in CeA, which consists of 95% GABAergic neurons (McDonald, 1982) . Pharmacological manipulations of CeA GABAergic transmission were used to assess their effects on the behavior of morphine reward measured by the paradigm of conditioned place preference (CPP), an established rodent model of drug reward (Tzschentke, 2007) .
MATERIALS AND METHODS

Animals and the Model of Chronic Pain
Male Wistar rats weighing 200-300 g were used in all experiments. Persistent inflammatory pain was induced by a single injection of complete Freund's adjuvant (CFA, 40 ml) into a hindpaw of the rat under brief isoflurane anesthesia. All procedures involving the use of animals conformed to the guidelines by the Institutional Animal Care and Use Committees of the University of Texas MD Anderson Cancer Center and the University of Science and Technology of China.
Paw-Withdrawal Test and Microinjection
Pain threshold in a freely moving rat was measured every 5 min by the paw-withdrawal test with a Hargreaves apparatus (Stoelting, Kiel, WI). The heat intensity of stimuli was set to obtain stable baseline latencies with a cutoff time of 12 s. CeA microinjection was performed as described previously (Bie et al, 2012; Zhu et al, 2007) . Briefly, a rat was implanted with a 26-G single-guide cannula (Plastics One, Roanoke, VA) aimed at CeA on both sides of the brain (anteroposterior, À 2.3 mm; lateral, ± 4 mm; dorsoventral, À 8.0 mm). Drugs were microinjected into CeA in a volume of 1 ml/side through a 33-G injector with an infusion pump at a rate of 0.2 ml/min. All CeA microinjection sites were histologically verified after the experiment by injecting a blue dye and controls of off-site injections were performed as described previously (Bie et al, 2009) . The effect of microinjected muscimol on rat CPP behavior was analyzed 10-20 min after its administration. The exact diffusion area of microinjected drugs was not determined; thus, a role of brain areas surrounding the targeted CeA cannot be completely excluded in these microinjection experiments.
CPP
The CPP paradigm was used with a three-chamber CPP apparatus (MED Associates, St Albans, VT) consisting of two test chambers (a black chamber with a stainless steel rod grid floor and a white chamber with a stainless steel mesh floor) and a central connecting gray chamber. The general CPP procedure has been described in our previous reports (Bie et al, 2012; Bie et al, 2009; Zhu et al, 2007) . The conditioning procedure consisted of four phases and lasted for 7 consecutive days. Phase 1 (habituation, days 1 and 2): after an i.p. injection of saline, a rat was placed in the central gray chamber and allowed to move freely among the three chambers for 30 min each day. Phase 2 (pretest, day 3): after a saline injections (i.p.), the rat was placed in the gray chamber and a pretest was conducted for 15 min to determine baseline preference by recording the time spent in each chamber. Rats that spent more than 60% of the test time in any one chamber were considered biased and were excluded from the results (o10% of all animals). Chamber pairing of different groups was alternated to adjust for remaining chamber bias. Phase 3 (morphine/saline conditioning, days 4-6): rats were randomly assigned to morphine group and saline group as control. The rat in morphine group was injected with saline (i.p.) and immediately confined to one test chamber in the morning for 30 min and then injected with morphine (3 mg/kg, i.p.) and 5 min later, confined to the other test chamber for 30 min in the afternoon. The interval between saline and morphine conditioning was longer than 6 h. Such a conditioning session was performed once daily for 3 days (in some experiments, four or five sessions were performed for 4 or 5 days, respectively). Phase 4 (posttest, day 7): a preference test was performed to determine morphine-induced CPP with the same procedure as that in pretest. Rats in saline group were similarly conditioned with saline only in all conditioning sessions. CPP behaviors are presented as CPP scores defined by the formula: CPP score ¼ time in morphine-paired chamber À time in saline-paired chamber in seconds. CFA or saline was injected 72 h before the first conditioning session. Indomethacin (10 mg/kg, i.p.) was injected 1 h before pretest, before posttest, or before each morphine-paring session in CFA-injected rats.
Brain Slice Preparations and Whole-Cell Recordings
The visualized whole-cell recording method has been described in our previous studies (Bie et al, 2012; Zhang et al, 2011; Zhu et al, 2007) . Slices (200-mm thick) of the rat brain containing CeA were cut with a vibratome and a single slice was perfused with preheated (35 1C) physiological saline containing the following (in mM): 126 NaCl, 2.5 KCl, 1.2 NaH 2 PO 4 , 1.2 MgCl 2 , 2.4 CaCl 2 , 11 glucose, and 25 NaHCO 3 saturated with 95% O 2 and 5% CO 2 , pH 7.2-7.4. Visualized whole-cell voltage-clamp recordings were obtained from identified CeA neurons with a glass pipette (resistance, 3-5 MO) filled with a solution containing the following (in mM): 126 KCl, 10 NaCl, 1 MgCl 2 , 11 EGTA, 10 HEPES, 2 ATP, and 0.25 GTP, pH adjusted to 7.3 with KOH, at an osmolarity of 280-290 mOsM/l. Electrical stimuli at a constant current (0.25 ms, 0.2-0.5 mA) were used to evoke GABA-mediated inhibitory postsynaptic currents (IPSCs). GABA IPSCs were recorded in the presence of the glutamate receptor antagonists D-( À )-2-amino-5-phosphonopentanoic acid (50 mM) and 6-cyano-7-nitroquinoxaline-2,3-dione (10 mM) at a holding potential of À 70 mV. Spontaneous miniature IPSCs (mIPSCs) were recorded in tetrodotoxin (1 mM) and analyzed with a sliding IPSC template defined by the acquisition software program.
Statistical Analyses and Materials
Comparison of IPSC and some CPP data between two groups were made by the Student's t-test (unpaired or paired, two-tailed). Behavioral results of CPP with repeated 
RESULTS
To determine the effect of pain on response to morphine reward measured by the CPP paradigm, we compared the rate of CPP induction by morphine-conditioning sessions in rats with persistent inflammatory pain induced by an intraplantar injection of CFA and in saline-injected control rats. CFA induced persistent thermal pain sensitization (hyperalgesia), which nearly peaked on the first day and lasted for at least 9 days after CFA injection ( Figure 1a ). In saline-injected control rats conditioned daily with morphine at 3 mg/kg (i.p.), a minimum of five conditioning sessions was required to induce significant CPP behavior; in contrast, in CFA-injected rats, three such sessions were sufficient to induce significant CPP ( Figure 1b ). To determine whether this facilitating effect of pain on the preference behavior was due to morphine inhibition of CFA-induced pain, we used the non-opioid analgesic indomethacin (10 mg/kg, i.p.) to inhibit the pain. Consistent with our previous report , indomethacin significantly inhibited CFA-induced pain sensitization ( Figure 1c ). With this indomethacin treatment, we found that inhibiting the pain 1 h before posttest had little effect on the magnitude of morphine-induced CPP in CFAinjected rats (Figure 1b) . To determine potential influence of pain-induced place aversion on the CPP behavior, we treated the rats with indomethacin before morphine conditioning. Indomethacin pretreatment 1 h before each session of morphine paring did not significantly alter the facilitating effect of pain on CPP acquisition in CFAinjected rats (Figure 1d) . Furthermore, the CPP facilitating effect of pain remained in CFA-injected rats after indomethacin pre-treatment of both saline and morphine groups before morphine conditioning, with three conditioning sessions sufficient to induce CPP (Figure 1e ). These results indicate that persistent pain facilitates the acquisition of preference behavior in response to morphine reward due more likely to a facilitated rewarding effect of morphine than to morphine inhibition of pain per se.
We then determined whether persistent pain altered synaptic activities that might have contributed to the CPP facilitation, focusing on GABA synaptic transmission in CeA neurons under whole-cell voltage-clamp recordings. In control CeA slices in the presence of D-2-amino-5-phosphonopentanoic acid (50 mM) and 6-cyano-7-nitroquinoxaline-2,3-dione (10 mM), the evoked IPSC was completely blocked by bath application of the GABA A receptor antagonist bicuculline (10 mM), confirming that it was mediated by GABA A receptors (Figure 2a) . In CeA slices from CFAinjected rats 3 days after CFA injection, we found that the averaged peak amplitude of GABA IPSCs was significantly smaller when compared with control IPSCs from salineinjected rats (saline: 480.4 ± 71.3 pA, n ¼ 11; CFA: 284.1 ± 70.6 pA, n ¼ 11; po0.05, Figure 2b ). In the presence of tetrodotoxin (1 mM), we examined the properties of mIPSCs to assess the synaptic site of this CFA-induced reduction in GABA synaptic function. In neurons from CFA-injected rats, both the frequency and amplitude of mIPSCs were significantly decreased when compared with controls (frequency: 53.2±19.4% of control, n ¼ 16, po0.05; amplitude: 69.9 ± 10.9% of control, n ¼ 16, po0.05; n ¼ 21, Figure 2c -f). These data indicate the possibility that persistent paininduced reduction in GABAergic synaptic function in CeA neurons may involve both pre-and postsynaptic sites.
Next, we assessed GABA synaptic activity in rats with morphine-induced CPP behavior. In rats after three morphine-conditioning sessions with no CPP, no difference was found in either mIPSC frequency or amplitude in CeA neurons from those of control rats conditioned with three saline sessions (frequency: 93.2±7.3% of control; amplitude: 117 ± 12.3% of control; n ¼ 13-16 cells in each group, Figure 3a) . However, in rats receiving five sessions of Pain facilitation of morphine reward Z Zhang et al morphine conditioning with CPP, both mIPSC frequency and amplitude were significantly decreased when compared with those of saline-conditioned rats (frequency: 70.3 ± 4.3% of control, po0.05; amplitude: 72.6 ± 14.1% of control, po0.05; n ¼ 12-16 in each group, Figure 3b ). In rat groups treated with the same amount of morphine in their home cages under an identical treatment paradigm, the mIPSC frequency and amplitude did not differ from those of control neurons (frequency: 96±12.3% of control; amplitude: 99.4±7.8% of control, n ¼ 16-17 in each group, Figure 3c ). These results suggest that discriminative learning during paring of the morphine effect with novel environment may be required for the reduction in GABAergic function of CeA neurons. We reasoned that if loss of GABA synaptic inhibition in CeA contributed to pain sensitization and to facilitated morphine induction of CPP, activation of CeA GABA A receptors under the same conditions should inhibit the CFA and morphine effects by alleviating CFA-induced hyperalgesia and reducing morphine CPP. To test this hypothesis, we determined behavioral effects of the GABA A receptor agonist muscimol microinjected into CeA in rats in vivo. As expected, in CFA-injected rats 3 days post CFA injection, an acute, bilateral infusion of muscimol (25 ng/side) into CeA increased pain threshold in response to thermal stimuli in the paw-withdrawal test, reducing the CFA-induced pain sensitization (Figure 4a ). Similar infusions of muscimol into CeA before each morphineconditioning session blocked CPP behavior induced by five morphine-conditioning sessions in rats (Figure 4b ). Representative microinfusion sites in CeA were illustrated in Figure 4c and d.
To further validate that CeA GABA A receptors were important for the facilitating effect of pain on morphine CPP, we examined the effect of CeA-infused muscimol on the CPP induced by sub-threshold morphine conditioning in rats with persistent pain. The sub-threshold conditioning with three morphine sessions induced significant CPP in CFA-injected rats and this CPP was inhibited by CeA infusion of muscimol (Figure 5a ). Conversely, CeA infusion of the GABA A receptor antagonist bicuculline mimicked the CFA effect, as control rats with bilateral CeA infusion of bicuculline (25 ng/side) before each morphine-conditioning session displayed a significant CPP behavior after three morphine-conditioning sessions (Figure 5b) . Thus, it appears that persistent pain facilitates the acquisition of CPP behavior related to morphine reward by reducing GABA synaptic inhibition in CeA neurons, an effect shared by morphine in its induction of reward-related CPP behavior.
DISCUSSION
We have shown in this study that persistent inflammatory pain increases response to morphine reward in acquisition of morphine-induced CPP behavior. Our results suggest that reduction in the inhibitory function of GABAergic synapses in CeA neurons, an effect shared by persistent pain and CPP-eliciting morphine, is involved in the cellular mechanism for pain facilitation of the reward response. Thus, it is possible that persistent pain reduces the GABAergic inhibitory function in CeA neurons, predisposing the CeA circuitry for opioid induction of reward-related behavior. 
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Both addictive opioids and chronic pain induce synaptic adaptations in the brain including CeA, which are important for the development of corresponding behaviors (Bie et al, 2012; Luscher and Malenka, 2011; Neugebauer et al, 2004; Russo et al, 2010; Zhu et al, 2007) . CeA consists of 95% GABAergic neurons (Ehrlich et al, 2009; Haubensak et al, 2010) . In rats with persistent inflammatory pain, we observed a significant decrease in GABA synaptic activity in CeA neurons, consistent with a previous report in a rat model of arthritic pain (Ren and Neugebauer, 2010) . Activation of CeA GABA A receptors reduces CFA-induced hyperalgesia in rats, as shown in a previous report (Pedersen et al, 2007) and in the current study. CeA modulation of pain is mediated via its projections to the periaqueductal gray of the descending pain-modulating system (Bourgeais et al, 2001; Neugebauer et al, 2004) . Our study further demonstrates that CPP-eliciting morphine, similar to pain, also reduces GABA synaptic activity. Whereas our analysis of mIPSCs indicates potential changes at both pre-and postsynaptic sites of GABA synapses, further studies with multidisciplinary approaches are necessary to identify pre-and postsynaptic mechanisms for the GABA reduction. It remains unknown how persistent pain and repeated opioids reduce GABA function in CeA neurons. In this regard, we have shown that persistent pain causes downregulation of glutamic acid decarboxylase 65, a predominantly presynaptic GABA-synthesizing enzyme for GAGA release (Soghomonian and Martin, 1998; Tian et al, 1999) , through an epigenetic mechanism of histone hypoacetylation, resulting in decreased GABA synaptic function (Zhang et al, 2011) . Thus, it is possible that similar activity-dependent epigenetic mechanisms are involved in pain-induced reduction of GABA function in CeA neurons.
As part of the brain's reward system, CeA mediates the process of emotional learning of stimulus-reward association (Baxter and Murray, 2002) and the circuitry may involve CeA projections to neurons in the ventral tegmental area (VTA), as stimulation of CeA GABAergic fibers modulates activity of VTA dopaminergic neurons involved in opioid reinforcement (Everitt et al, 1999; Gonzales and Chesselet, 1990; Leshan et al, 2010) . Our data of blocking and activating CeA GABA A receptors on CPP behavior indicate that changes in CeA GABA synaptic function is sufficient to influence the behavior of opioid reward. It is noteworthy that home cage injection of morphine is ineffective on GABA function in CeA neurons, indicating that context-related discriminative learning of the rewarding effect of morphine during morphine paring with distinctive chambers may be required for the reduction in GABA synaptic function in CeA. Recent studies have shown that both CeA and the basolateral nucleus of the amygdala are critical in the process of contextual learning for acquisition and expression of positive effect (eg, drug Pain facilitation of morphine reward Z Zhang et al reward) as well as aversive responses of negative effect (eg, fear; Baxter and Murray, 2002; Maren et al, 2013; Murray, 2007; Wilensky et al, 2006) . As shown in basolateral nucleus of the amygdala and hippocampal neurons, a common cellular mechanism for fear learning and memory is glutamate-mediated neuronal hyperexcitability induced by reduced GABAergic inhibitory function through disinhibition (Reger et al, 2012; Rodriguez Manzanares et al, 2005; Santos et al, 2013) . A disinhibition mechanism of reduced GABA function also is responsible for the excitation of dopamine neurons in VTA in behaviors of context-reward association (Luo et al, 2011) . Thus, it is possible that the reduced GABA function in CeA observed in this study may lead to hyperactivity of neurons in CeA-targeted brain areas such as VTA and hippocampus in the process of discriminative learning of morphine reward. CPP behavior can be driven by motivational effects of drug reward and by removal of an aversive state such as opioid inhibition of aversive pain. Thus, pain relief is rewarding and analgesic agents can reliably induce CPP behavior in animal models of neuropathic and inflammatory pain (Fields, 2004; King et al, 2009; Sufka, 1994) . Our results show that, when pain is acutely inhibited either before or after morphine-conditioning sessions, acquisition of morphine CPP is still facilitated in CFA-injected rats. This indicates that the facilitated CPP response we observed is due more to a heightened rewarding effect of morphine than to morphine inhibition of acute pain and potentially its associated aversion per se. However, morphine and indomethacin used in this study may have differential efficacies in pain inhibition and these experiments do not exclude contribution of rewarding effect from morphine inhibition of lasting emotional component of pain. As such, this heightened rewarding effect of morphine could be the result of interactive changes in the CeA circuitry mediating both drug reward and emotional pain, an issue that needs further investigation in future studies. Whereas this study focused on the initial acquisition rate for CPP behavior of opioid reward, previous studies examined pain effects on the magnitude of already acquired CPP behavior and established behavior of opioid intake with controversial results reported. Some studies showed that pain reduced opioid-induced CPP or opioid self-administration (Martin et al, 2007; Narita et al, 2005; Ozaki et al, 2003) , but other studies found that pain enhanced opioid CPP and selfadministration (Cahill et al, 2013; Colpaert et al, 2001; Kupers and Gybels, 1995; Sufka, 1994) . The reasons for the discrepancy are unclear and it appears likely that the pain effect on acquired behaviors of opioid reward is dependent on opioid doses used in different animal models of pain. Our current results show a pain-facilitated process of acquiring CPP behavior of morphine reward and a synaptic mechanism for pain-reward interaction that may be involved in the facilitated acquisition of preference behavior.
Clinically, the effect of chronic pain on the liability of opioid use and abuse has been a pressing issue, as nonmedical use of prescription opioids has dramatically increased in recent years, including incidences of misuse of prescription opioids for pain control (Compton and Volkow, 2006; Sullivan and Ferrell, 2005; Woolf and Hashmi, 2004) . Compared with the general population, a smaller subpopulation of pain patients taking repeated opioids develop addiction to opioids, often with preexisting conditions (Ballantyne and LaForge, 2007; Hojsted and Sjogren, 2007) . How pain affects the development of opioid addiction in patients and what are the underlying neurobiological mechanisms are still unknown. In clinical settings, many factors would influence behaviors of drug taking and an important such factor is the comorbid negative emotions such as depression and anxiety in chronic pain patients (Huyser and Parker, 1999; McWilliams et al, 2003; Wilson et al, 2001) . Although negative mood of depression may inhibit drug abuse by counteracting positive emotion-associated drug reward, stressful stimuli can increase opioid-seeking behavior ## po0.01.
Pain facilitation of morphine reward Z Zhang et al (Koob, 1999; Kreibich et al, 2009; Leknes and Tracey, 2008; Lu et al, 2003) , suggesting that psychological dysfunction may differentially influence behavior of opioid intake and susceptibility to opioid abuse. However, such pain-associated emotional behaviors of negative effect have not been systemically characterized or consistently observed during the time frame of experiments in currently used animal models of chronic pain (Urban et al, 2011) . In addition, pain may have differential effects on established behaviors of opioid seeking/intake and on acquisition of those behaviors. Although this study in a simpler experimental setting of animal models cannot directly model the much complex clinical situations, it provides original evidence indicating that pain may serve as one predisposing factor to facilitate acquisition responses to opioid reward through CeA-related learning and processing of opioid reward involving reduced GABA synaptic function and consequently neuronal disinhibition, a converged effect on CeA neurons by both pain and opioids.
